The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Hybridization-based target enrichment panel with our intrinsic probe design, rebalancing, and molecular barcode technologies to efficiently analyze not only hard-to-capture areas but also challenging samples, such as damaged DNA or RNA.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
End-to-end customized target enrichment panel with assay optimization, validation and even complete BI support. Over 1,000 custom panels developed world-wide. White-labeled customized product for business expansion also available.
View Detail >
Providing NGS-based diagnostics solutions for biopharma companies. Celemics can develop and deliver a flexible customization and commercialization services while maintaining the market-leading performance for our clients interested in clinical and companion diagnostics.
View Detail >
Tailored-fit customized assay development from designing to validation run; including not only the custom panel design but also species-specific or sequencer-specific blockers, followed by reagent conditioning to optimize the individual experiment and sequencer.
View Detail >
The most comprehensive whole exome panel that covers the target regions of all major WES panels in the market. With our proprietary technologies, we provide industry-leading performance and efficiency with complete BI solution.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Explore the most up-to-date publications featuring Celemics’ products and services
View Detail >
Sharing interesting stories about the world of NGS and how Celemics delivers the innovative NGS solutions to the world of science.
View Detail >
Explore a diverse range of engaging video content, from fascinating experiments showcasing cutting-edge research to heartfelt customer testimonials.
View Detail >
Find useful information, insights and tools for your Celemics’ products and services
View Detail >
Stay up-to-date with the latest updates on our activities, events and achievements
View Detail >
Let’s change the NGS market together – our global presence and partners world-wide
View Detail >
Waiting for your experience with Celemics, an innovative leader in NGS industry
View Detail >Pharmacogenomics
Experimental & Molecular Medicine Synergistic toxicity with copper contributes to NAT2-associated isoniazid toxicity Yoon JG, Jang DG, Cho SG, Lee C, Noh SH, Seo SK, Yu JW, Chung HW, Han…
Theranostics Development of the phenylpyrazolo [3, 4-d] pyrimidine-based, insulin-like growth factor receptor/Src/AXL-targeting small molecule kinase inhibitor Lee HJ, Pham PC, Pei H, Lim B, Hyun SY, Baek B, et al.…
- First-line pembrolizumab, trastuzumab, and chemotherapy in advanced HER2-2 positive gastric cancer with sequential genomic profiling Chung HC, Bang YJ, S Fuchs C, Qin SK, Satoh T, Shitara K, et…
British Journal of Cancer p53 expression status is associated with cancer-specific survival in stage III and high-risk stage II colorectal cancer patients treated with oxaliplatin-based adjuvant chemotherapy Oh HJ, Bae…
